Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis.
作者信息
Hoffmann Almuth, Dietrich Sascha, Hain Susanne, Rieger Michael, Hegenbart Ute, Sellner Leopold, Ho Anthony D, Müller-Tidow Carsten, Dreger Peter
机构信息
Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg
Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg.
出版信息
Haematologica. 2019 Jul;104(7):e304-e306. doi: 10.3324/haematol.2018.209486. Epub 2019 Jan 10.
Abstract
摘要
相似文献
1
Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis.高危慢性淋巴细胞白血病的异基因移植：一项单中心意向性治疗分析。
Haematologica. 2019 Jul;104(7):e304-e306. doi: 10.3324/haematol.2018.209486. Epub 2019 Jan 10.
2
Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning.与低强度非清髓性预处理相比，含烷化剂化疗的减低强度预处理方案并未改变慢性淋巴细胞白血病患者异基因造血细胞移植后的生存结局。
J Cancer Res Clin Oncol. 2019 Nov;145(11):2823-2834. doi: 10.1007/s00432-019-03014-x. Epub 2019 Aug 29.
3
Progressive chronic lymphocytic leukemia after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后进展性慢性淋巴细胞白血病。
J Natl Compr Canc Netw. 2012 Oct 1;10(10):1203-6. doi: 10.6004/jnccn.2012.0127.
4
Role of allogeneic hematopoietic stem-cell transplantation in chronic lymphocytic leukemia.
J Clin Oncol. 2008 Oct 20;26(30):4864-5. doi: 10.1200/JCO.2008.17.7733. Epub 2008 Sep 15.
5
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience.高强度预处理慢性淋巴细胞白血病患者的减低剂量预处理异基因移植：单中心经验
Hematol Oncol. 2011 Jun;29(2):107-10. doi: 10.1002/hon.950. Epub 2010 Jun 21.
6
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.伊布替尼治疗异基因造血干细胞移植后晚期复发慢性淋巴细胞白血病的疗效
Hematol Oncol. 2021 Apr;39(2):267-269. doi: 10.1002/hon.2826. Epub 2020 Nov 20.
7
Allogeneic hematopoietic cell transplantation for Richter transformation of chronic lymphocytic leukemia: an intention-to-transplant analysis.慢性淋巴细胞白血病Richter转化的异基因造血细胞移植：一项意向性移植分析。
Bone Marrow Transplant. 2023 Jul;58(7):817-819. doi: 10.1038/s41409-023-01978-6. Epub 2023 Apr 1.
8
Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia.
Expert Rev Anticancer Ther. 2005 Oct;5(5):875-91. doi: 10.1586/14737140.5.5.875.
9
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.减低强度预处理和异基因干细胞移植后慢性淋巴细胞白血病移植物抗白血病效应的证据：德国移植协作研究组
J Clin Oncol. 2003 Jul 15;21(14):2747-53. doi: 10.1200/JCO.2003.12.011.
10
Delayed graft versus leukemia effect after allogeneic peripheral stem cell transplantation in a patient with chronic lymphocytic leukemia.
Haematologica. 2000 Mar;85(3):330-2.
引用本文的文献
1
Cellular Therapies in Chronic Lymphocytic Leukemia and Richter's Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem Cell Transplant.慢性淋巴细胞白血病和里氏转化中的细胞疗法：嵌合抗原受体T细胞、自然杀伤细胞和异基因干细胞移植的最新进展
Cancers (Basel). 2023 Mar 18;15(6):1838. doi: 10.3390/cancers15061838.
2
The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT.2009 年至 2019 年期间，欧洲异基因造血细胞移植治疗慢性淋巴细胞白血病的现状：来自 EBMT 慢性恶性肿瘤工作组的观点。
Bone Marrow Transplant. 2023 Jun;58(6):621-624. doi: 10.1038/s41409-023-01955-z. Epub 2023 Mar 28.
3
Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features.具有高危分子特征的慢性淋巴细胞白血病的治疗方法
Front Oncol. 2021 Dec 9;11:780085. doi: 10.3389/fonc.2021.780085. eCollection 2021.
4
Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia.高危慢性淋巴细胞白血病先前接受靶向治疗后的异基因造血细胞移植。
Blood Adv. 2020 Sep 8;4(17):4113-4123. doi: 10.1182/bloodadvances.2020002184.
5
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.新型药物时代的慢性淋巴细胞白血病异基因造血干细胞移植。
Blood Adv. 2020 Aug 25;4(16):3977-3989. doi: 10.1182/bloodadvances.2020001956.
6
Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial.异基因造血干细胞移植后微小残留病驱动的免疫干预对高危慢性淋巴细胞白血病的疗效：一项前瞻性多中心试验的结果
Haematologica. 2021 Jul 1;106(7):1867-1875. doi: 10.3324/haematol.2019.239566.
本文引用的文献
1
High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.在通路抑制剂时代的高危慢性淋巴细胞白血病：整合分子和细胞疗法。
Blood. 2018 Aug 30;132(9):892-902. doi: 10.1182/blood-2018-01-826008. Epub 2018 Jul 11.
2
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.伊布替尼用于慢性淋巴细胞白血病或套细胞淋巴瘤患者异基因造血细胞移植桥接治疗：一项由 EBMT 慢性恶性肿瘤和淋巴瘤工作组开展的研究。
Bone Marrow Transplant. 2019 Jan;54(1):44-52. doi: 10.1038/s41409-018-0207-4. Epub 2018 May 4.
3
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.维奈托克治疗伴有 17p 缺失的慢性淋巴细胞白血病患者：来自 II 期关键性试验全人群的结果。
J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1.
4
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.伊布替尼单药治疗初治和复发/难治性慢性淋巴细胞白血病：5 年经验。
Blood. 2018 Apr 26;131(17):1910-1919. doi: 10.1182/blood-2017-10-810044. Epub 2018 Feb 2.
5
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.高危慢性淋巴细胞白血病的异基因造血细胞移植：GCLLSG CLL3X试验的10年随访
Blood. 2017 Sep 21;130(12):1477-1480. doi: 10.1182/blood-2017-04-775841. Epub 2017 Jul 17.
6
Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT).药物研发对干细胞移植应用的影响：欧洲血液与骨髓移植学会（EBMT）的一份报告
Bone Marrow Transplant. 2017 Feb;52(2):191-196. doi: 10.1038/bmt.2016.258. Epub 2016 Nov 7.
7
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?在向新治疗时代过渡期间管理高危慢性淋巴细胞白血病：干细胞移植还是新型药物？
Blood. 2014 Dec 18;124(26):3841-9. doi: 10.1182/blood-2014-07-586826. Epub 2014 Oct 9.
8
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.利妥昔单抗免疫化疗后慢性淋巴细胞白血病患者微小残留病（MRD）定量的标准化MRD流程及ASO IGH RQ-PCR：一项比较分析
Leukemia. 2009 Nov;23(11):2007-17. doi: 10.1038/leu.2009.140. Epub 2009 Jul 30.
Zotero 插件